The HIMS application organized a smartphone in New York on February 12, 2025.
Gabby Jones | Bloomberg | Getty images
Hims and his health The shares closed 5% on Tuesday after the company announced that patients can access Eli LillyZepbound weight loss medication and Drug Mounjaro diabetes, as well as the generic injection liraglutide, through its platform.
Zepbound, Mounjaro and Liraglutide are part of the class of weight loss called LPG-1, which have exploited in popularity in recent years. Hims & Hers launched a weight loss program at the end of 2023, but their GLP-1 offers have evolved as the company has sustained with a volatile supply and a regulatory environment.
The weekly injections of Lilly Zepbound and Mounjaro will cost the patients $ 1,899 per month, according to the Hims & Hers website. The generic liraglutide will cost $ 299 per month, but requires a daily injection and can be less effective than other GLP-1 medications.
“As we look to the future, we plan to continue expanding our weight loss offer to offer an even more holistic and personalized experience,” wrote Dr. Cram Primack, senior vice president of weight loss in HEMS & Hers, in a blog post.
A Lilly spokesman said in a statement that the company does not have “affiliation” with Hims & Hers and pointed out that Zepbound is available at lower costs for insured people for the product or for those who buy directly from the company.
In May, Hims & Hers began to prescribe composite semaglutida, the active ingredient in LGP-1 loss drugs of Novo Nordisk Ozempic and Wogovy. The offer was immensely popular and helped generate more than $ 225 million in income for the company in 2024.
But traditionally compound medications can only be produced by mass when brand medication treatments are scarcity. The United States Food and Medicines Administration announced in February that the scarcity of semaglutidal injection products had been resolved.
That meant that HIMS and hers had to stop offering compound medications, although some consumers can still access personalized doses if it is clinically applicable.
During the company's quarterly so -called investors in February, Hims & Hers said that their weight loss offers will consist mainly of their oral medications and liraglutida. The company said it expects its weight loss offers to generate at least $ 725 million in annual revenues, excluding the contributions from the composite semaglutid.
But the company is still pressing for compound medications. A emerging window on the Hims & Hers website, which was seen by CNBC, encourages users to “use their voice” and urge Congress and the FDA to preserve access to composite treatments.
With the demonstration on Tuesday, HEMS and HERS shares have increased approximately 27% by 2025 after increasing 172% last year.
LOOK: HIMS & HERS Share about concerns about the weight loss business
